Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;36(5):581-7.
doi: 10.1016/j.leukres.2012.02.001. Epub 2012 Mar 2.

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study

Susan Bell Nyland  1 , Daniel J Krissinger, Michael J Clemente, Rosalyn B Irby, Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, Eric Schaefer, Jason Liao, David Cuthbertson, Pearlie Epling-Burnette, Ronald Paquette, Alan F List, Jaroslaw P Maciejewski, Thomas P Loughran Jr
Affiliations

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study

Susan Bell Nyland et al. Leuk Res. 2012 May.

Abstract

Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no competing financial interests.

Figures

Fig 1
Fig 1
Peptide Array Epitope Mapping. Overlapping peptides were tested for seroreactivity against LGL leukemia and normal donor sera (Peptide vs. Serum Group). The signal strength of the sera was interpreted as reactivity. Neg Ctl: duck hepatitis B virus core peptide. Pos Ctl: Anti-IgG1. ρ: probability, χ: mean value, σ: standard deviation.
Fig 2
Fig 2
BA21 Epitope ELISAs. Serum IgG levels are proportional to the Average OD 450nm (Y axis). Sera were serially diluted in PBS 250X to 64,000X. NS: no sera. LGL: LGL leukemia sera. Norm: Normal donor sera.
Fig 3
Fig 3
LGL Leukemia Serum Reactivity to BA21.1. ELISA data is shown. Females: n=15, average age was 49.5 for female LGL leukemia patients and 49.2 for normal female donors. Males: n=27, average age was 62.8 for male LGL leukemia patients and 60 for normal male donors. ρ: probability, χ: mean value, σ: standard deviation.
Fig 4
Fig 4
BA21 IgG levels in LGL Leukemia and BMF Diseases. ELISA data is shown. N: normal donors, AA: aplastic anemia, LGL: large granular lymphocyte leukemia, MDS: myelodysplastic syndrome, PNH: paroxysmal nocturnal hemoglobinuria (all described in text). Open circles: individual values > 99% CI for each group. ρ: probability, χ: mean value, σ: standard deviation (also shown as bars).
See this image and copyright information in PMC

References

    1. Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol. 2011;152:273–83. - PubMed
    1. Melenhorst JJ, Sorbara L, Kirby M, et al. Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8(+) lymphocyte populations. Br J Haematol. 2001;112:189–94. - PubMed
    1. Kothapalli R, Bailey RD, Kusmartseva I, et al. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22:33–9. - PubMed
    1. Maciejewski JP, O’Keefe C, Gondek L, et al. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol. 2007;45:5–14. - PubMed
    1. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology. 2003;8:173–81. - PubMed

Publication types

MeSH terms

Substances